Pictet Asset Management Holding SA Lowers Stock Position in Revvity Inc. $RVTY

Pictet Asset Management Holding SA trimmed its holdings in shares of Revvity Inc. (NYSE:RVTY) by 34.2% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 897,343 shares of the company’s stock after selling 466,439 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Revvity were worth $78,561,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of RVTY. CYBER HORNET ETFs LLC bought a new stake in Revvity during the 2nd quarter valued at $32,000. Cromwell Holdings LLC raised its position in shares of Revvity by 141.4% in the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after acquiring an additional 198 shares in the last quarter. MUFG Securities EMEA plc bought a new position in shares of Revvity in the 2nd quarter worth $34,000. Headlands Technologies LLC purchased a new stake in shares of Revvity during the 2nd quarter worth $49,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Revvity during the 4th quarter worth $51,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Analysts Set New Price Targets

RVTY has been the topic of several analyst reports. Robert W. Baird set a $117.00 target price on Revvity in a research note on Wednesday, May 6th. The Goldman Sachs Group lowered their price target on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating on the stock in a report on Tuesday, April 14th. Wolfe Research assumed coverage on shares of Revvity in a research report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Sanford C. Bernstein began coverage on shares of Revvity in a research note on Friday. They set a “market perform” rating and a $115.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their target price on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $108.33.

Revvity Trading Down 1.7%

Shares of NYSE:RVTY opened at $111.12 on Tuesday. The business’s 50-day moving average is $97.89 and its 200 day moving average is $97.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.72 and a quick ratio of 1.41. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $118.30. The firm has a market capitalization of $12.40 billion, a P/E ratio of 53.17, a P/E/G ratio of 2.47 and a beta of 1.11.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The business had revenue of $711.12 million during the quarter, compared to the consensus estimate of $704.07 million. During the same quarter last year, the company earned $1.01 earnings per share. The company’s quarterly revenue was up 7.0% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, research analysts predict that Revvity Inc. will post 5.25 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, July 17th. Revvity’s dividend payout ratio (DPR) is presently 13.40%.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.